Signing ceremony for MoU between Cyto-Facto Inc. and Thermo Fisher Scientific Japan

We are pleased to announce that Cyto-Facto Inc. has signed a Memorandum of Understanding (MoU) with Thermo Fisher Scientific Japan to cooperate on process development for the manufacture of viral vectors for clinical applications. The signing ceremony was held on November 20, 2024 at the Kobe Medical Innovation Center (KCMI). This new partnership is aimed at developing processes for suspension-based scale up of viral vectors in single-use bioreactors to expedite the provision of clinical-grade viral vectors for gene therapies.

Sysmex and J-TEC Sign a Basic Agreement to Advance Manufacturing Capabilities for Regenerative Medicine and Cell Therapy

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) and Japan Tissue Engineering Co., Ltd. (HQ: Gamagori, Aichi Prefecture; President & CEO: Ken-ichiro Hata; hereinafter “J-TEC”) announced that they signed a basic agreement (“the Agreement”) on December 3, 2024, with the aim of advancing (i.e., mechanizing and automating) manufacturing capabilities for regenerative medical products by utilizing innovative technologies, in order to accelerate the industrialization of regenerative medicine and cell therapy and to enhance sustainability. Going forward, both companies will start concrete strategic collaboration based on this Agreement.